Artikel ; Online: Profile of Relugolix in the Management of Advanced Hormone-Sensitive Prostate Cancer: Design, Development, and Place in Therapy.
Drug design, development and therapy
2023 Band 17, Seite(n) 2325–2333
Abstract: Androgen deprivation therapy, primarily via a gonadotropin-releasing hormone receptor agonist or antagonist together with or without an androgen receptor antagonist, remains the mainstay of medical treatment for advanced prostate cancer. Meanwhile, ... ...
Abstract | Androgen deprivation therapy, primarily via a gonadotropin-releasing hormone receptor agonist or antagonist together with or without an androgen receptor antagonist, remains the mainstay of medical treatment for advanced prostate cancer. Meanwhile, relugolix has been developed as the first orally active, non-peptide, selective antagonist for the gonadotropin-releasing hormone receptor. Previous randomized studies involving patients with prostate cancer have demonstrated comparable efficacy in androgen suppression between relugolix vs other gonadotropin-releasing hormone antagonists or agonists. This review summarizes available data on the design and development of relugolix and its therapeutic application, and discusses if relugolix represents a promising oral alternative to injectable androgen deprivation therapy. Based on current published evidence, further investigation is likely required to determine the actual clinical benefits of relugolix therapy against prostate cancer. |
---|---|
Mesh-Begriff(e) | Male ; Humans ; Prostatic Neoplasms/drug therapy ; Receptors, LHRH ; Gonadotropin-Releasing Hormone/agonists ; Androgen Antagonists/pharmacology ; Androgen Antagonists/therapeutic use ; Androgens/therapeutic use |
Chemische Substanzen | Receptors, LHRH ; Gonadotropin-Releasing Hormone (33515-09-2) ; relugolix ; Androgen Antagonists ; Androgens |
Sprache | Englisch |
Erscheinungsdatum | 2023-08-04 |
Erscheinungsland | New Zealand |
Dokumenttyp | Journal Article ; Review |
ZDB-ID | 2451346-5 |
ISSN | 1177-8881 ; 1177-8881 |
ISSN (online) | 1177-8881 |
ISSN | 1177-8881 |
DOI | 10.2147/DDDT.S373546 |
Datenquelle | MEDical Literature Analysis and Retrieval System OnLINE |
Zusatzmaterialien
Kategorien
Über subito bestellen
Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.